Abnormal lipid metabolism and renal disorders
Open accessAbstract
Abnormal renal diseases including nephrotic syndrome and chronic renal failure are associated with hyperlipidemia, significance of abnormal lipid metabolism has been thought to be limited in some inherited renal diseases. However, recent studies have postulated that glomerulosclerosis is induced by hyperlipidemia and is in common with atherosclerosis. This involvement is found in the progressive renal disorders, e.g., focal glomerular sclerosis, diabetic nephropathy and glycogen storage disease. Interaction between macrophages and mesangial cells may play an important role in such conditions. This evidence is supported by experimental models with hyperlipidemia. On the other hand, discovery and new hereditary metabolic disorders, such as type III hyperlipoproteinemia and lipoprotein glomerulopathy, shows that apolipoprotein (apo) E abnormalities are responsible for the glomerular lesions. Especially, lipoprotein glomerulopathy has specific features different from those of lipid-induced renal diseases. In this disease, apo E Sendai which results from new substitution (Arginine 145-->Proline) may induce intraglomerular lipoprotein thrombi characteristic of lipoprotein glomerulopathy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical symptoms of LPG vary from mild proteinuria to nephrotic syndrome and chronic renal failure.
“Clinical symptoms of LPG vary from mild proteinuria to nephrotic syndrome and chronic renal failure ( 20,54,55 ).”
From Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice (2014) · cites this paper as [20]
The Hereditary metabolic disorders section (around p. 329) describes lipoprotein glomerulopathy’s renal lesions and other clinical features, but does not give the claimed range from mild proteinuria to nephrotic syndrome and chronic renal failure. Searches for those terms found them elsewhere in the paper, not as a description of lipoprotein glomerulopathy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia
Saito, T., Sato, H., Kudo, K.-I., Oikawa, S.-I., Shibata, T., Hara, Y., Yoshinaga, K., & Sakaguchi, H. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80134-9 · Cited by 148 · see citing works
Self-citationAbnormal Lipoprotein and Apolipoprotein Pattern in Lipoprotein Glomerulopathy
Oikawa, S., Suzuki, N., Sakuma, E., Saito, T., Namai, K., Kotake, H., Fujii, Y., & Toyota, T. (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80649-4 · Cited by 60 · see citing works
Self-citationSaito, T., Sato, H., Oikawa, S., Kudo, K., Kurihara, I., Nakayama, K., Abe, K., Yoshinaga, K., & Sakaguchi, H. (1993) · American Journal of Nephrology · doi:10.1159/000168591 · Cited by 57 · see citing works
Self-citationStimulation of hepatic lipogenesis and acetyl-coenzyme A carboxylase by vasopressin
Assimacopoulos-Jeannet, F., Denton, R. M., & Jeanrenaud, B. (1981) · Biochemical Journal · doi:10.1042/bj1980485 · Cited by 29 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [8]Churg, J., Bernstein, J. & Glassock, R.J. (1995) *Renal Disease: Classification and Atlas of Glomerular Diseases*, 2nd ed., Igaku-Shoin, New York, Tokyo, pp. 450–475.
- [12]Elshourbagy, N.A., Liao, W.S., Mahley, R.W. & Taylor, J.M. (1985) Apolipoprotein E mRNA is abundant in the brain and adrenal, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. *Proc. Natl. Acad. Sci. USA*, **82**, 203–207.
- [13]Faraggiana, T. & Churg, J. (1987) Renal lipidoses: A review. Hum. Pathol., 18, 661-679.
- [36]Oikawa, S., Matsunaga, A., Saito, T., Sato, H., Seki, T., Hoshi, K., Hayasaka, K., Kotake, H., Midorikawa, H., Sekikawa, A., Hara, S., Abe, K., Toyota, T., Jingami, H., Nakamura, H. & Sasaki, J. (1997) Apolipoprotein E Sendai (Arginine 145→ Proline): A new variant associated with lipoprotein glomerulopathy. J. Am. Soc. Nephrol., 8. (in press)
Cited by
Sorted by citations
Hypocholesterolemic Effect of <i>Spirulina</i> in Patients with Hyperlipidemic Nephrotic Syndrome
Samuels, R., Mani, U. V., Iyer, U. M., & Nayak, U. S. (2002) · Journal of Medicinal Food · doi:10.1089/109662002760178177 · Cited by 123 · see citing works
Tavori, H., Fan, D., Giunzioni, I., Zhu, L., Linton, M. F., Fogo, A. B., & Fazio, S. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m049874 · Cited by 10 · see citing works
- Authors
- Saito, T.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Saito, Takao
- ORCID
- Saito, Takao
- Venue
- The Tohoku Journal of Experimental Medicine
- Publisher
- Tohoku University Medical Press
- Published
- 1997
- Volume
- 181
- Issue
- 3
- Pages
- 321-337
- ISSN
- 0040-8727 (ISSN-L)
- 1349-3329
- OpenAlex
- W2044882017
- Cited by
- 35
- References
- 4
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 2 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Tohoku Journal of Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- abnormal lipid metabolism, hyperlipidemia, kidney disease, nephrotic syndrome, chronic kidney disease, glomerulosclerosis, atherosclerosis, focal glomerulosclerosis, diabetic nephropathy, glycogen storage disease, macrophages, mesangial cells, type III hyperlipoproteinemia, lipoprotein glomerulopathy, apolipoprotein E, inborn errors of metabolism
- MeSH terms
- Fabry Disease, Animals, Apolipoproteins E, Diabetic Nephropathies, Disease Models, Animal, Glomerulosclerosis, Focal Segmental, Glycogen Storage Disease Type I, Humans, Hyperlipidemias, Hyperlipoproteinemia Type III, Kidney Diseases, Lipids, Lipid Metabolism, Apolipoprotein E2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
